The Exact Exponent of Sparse Grid Quadratures in the Weighted Case
β Scribed by Leszek Plaskota; Grzegorz W. Wasilkowski
- Publisher
- Elsevier Science
- Year
- 2001
- Tongue
- English
- Weight
- 111 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0885-064X
No coin nor oath required. For personal study only.
β¦ Synopsis
This paper provides a lower bound on the exponent of tractability for Sparse Grid Quadratures for multivariate integration of functions from a certain class of weighted tensor product spaces. This lower bound is sharp since it matches a corresponding upper bound of G. W. Wasilkowski and H. Woz Β΄niakowski (1999, J. Complexity 15, 402-447). It also shows that, for slowly decreasing weights, the exponent of Sparse Grid Quadratures is far from being optimal.
π SIMILAR VOLUMES
## Abstract One of the important issues in the implementation of the differential quadrature method is the imposition of the given boundary conditions. There may be multiple boundary conditions involving higherβorder derivatives at the boundary points. The boundary conditions can be imposed by modi
We introduce the combination technique for the numerical solution of ddimensional eigenproblems on sparse grids. Here, O(d β’ (log N ) d-1 ) different problems, each of size O(N ), have to be solved independently. This is in contrast to the one problem of size O(N d ) for a conventional finite elemen
We consider the problem of testing for heterogeneity of K proportions when K is not small and the binomial sample sizes may not be large. We aasume that the binomial proportions are normally distributed with variance a? The asymptotic relath e efficiency (ARE) of the usual chi-square test iefoundrel
Overweight/obesity, caused by the 'nutrition transition', is identified as one of the leading risk factors for noncommunicable mortality. The nutrition transition in developing countries is associated with a major shift from the consumption of staple crops and whole grains to highly and partially pr
Phentermine and fenfluramine are widely used in the treatment of obesity. Despite the fact that primary pulmonary hypertension and mitral valve insufficiency have been associated with fenfluramine use, many of these patients need medication to achieve weight loss. Small degrees of weight loss have b